Strong Revenue Growth Reported by STERIS
STERIS plc (NYSE: STE) recently announced its financial results for the second quarter of Fiscal Year 2026. The company recorded total revenue from continuing operations of $1.5 billion, marking a significant 10% increase from $1.3 billion in the same quarter a year prior. This growth reflects a solid 9% increase in constant currency organic revenue.
Performance Highlights
Dan Carestio, the President and CEO of STERIS, expressed satisfaction with the company's performance, noting that despite facing challenges, the results exceeded expectations and margins showed a positive trend. The management team anticipates an upward revision in the outlook for the fiscal year.
Net Income and Earnings Per Share
The earnings report highlighted an increase in net income from continuing operations to $191.9 million, translating to $1.94 per diluted share, up from $150.2 million or $1.51 per diluted share in the second quarter of FY25. Adjusted net income for the quarter was also robust, reaching $244.5 million or $2.47 per diluted share, comparing favorably to $212.2 million or $2.14 per diluted share in the previous year.
Segment Performance Analysis
Dissecting the company’s revenue streams reveals that the Healthcare segment showed impressive growth, achieving revenue of $1,033.8 million, a 9% increase year-over-year. This growth was propelled by a significant 13% increase in service revenue, bolstered by advancements in productivity and successful restructuring efforts, despite rising costs related to tariffs and inflation.
In the Applied Sterilization Technologies (AST) segment, reported revenue rose by 10% to $281.5 million, benefitting from a 13% increase in service revenue, although capital equipment revenue faced a notable decline of 76%. However, segment operating income increased significantly, reflecting better pricing and a favorable sales mix.
The Life Sciences division also performed well, reporting a 13% revenue increase to $145.0 million due in part to a 39% surge in capital equipment revenue. The improved operating income of $59.9 million for this segment reflects efficient volume handling and pricing strategies.
Cash Flow and Financial Outlook
For the first half of FY26, STERIS provided solid cash flow results, reporting net cash provided by operations at $707.8 million, compared to $554.4 million in the same period last year. Free cash flow also saw a notable increase, reaching $527.7 million, which supports the company's future investment strategies and shareholder returns.
The company has raised its fiscal 2026 revenue outlook, projecting an increase from continuing operations to be within the range of 8-9%, with constant currency organic revenue growth now expected between 7-8%. Adjusted earnings per diluted share expectations have also been adjusted upwards to between $10.15 and $10.30. This outlook incorporates an expected negative impact from tariffs estimated to affect pre-tax profits by about $45 million.
Upcoming Conference Call
STERIS has scheduled a conference call for management to discuss these results in detail and provide further insights into the company's strategic direction. The call will be held at a specified time on November 6, 2025, and will offer interested stakeholders an opportunity to engage directly with the leadership team.
About STERIS
STERIS plc is dedicated to supporting healthcare initiatives globally, focusing on innovations in infection prevention. Their mission is to foster a healthier and safer world through advanced healthcare solutions. For inquiries or further information, interested parties can reach out via their designated corporate communications channels.
Frequently Asked Questions
What were STERIS's total revenue figures for FY26 Q2?
STERIS reported total revenue of $1.5 billion, a 10% increase from the previous year.
How did net income change for STERIS in the second quarter?
Net income increased to $191.9 million, translating to earnings of $1.94 per diluted share.
What segments contributed to STERIS's revenue growth?
Healthcare, Applied Sterilization Technologies, and Life Sciences segments all reported significant growth in revenue.
What is the projected free cash flow for FY26?
The company anticipates free cash flow to reach approximately $850 million for FY26.
How can investors access the STERIS conference call?
Investors can join the call by visiting the official STERIS website or dialing the provided numbers for live participation.
